Intellectual Property Estate

Evox has created a comprehensive intellectual property portfolio encompassing key aspects of exosome-based drug delivery technology. Coupled with tailored targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across several disease areas, using a wide array of therapeutic modalities.

Key aspects of Evox’s intellectual property portfolio includes:

  • Exosomes for delivery of nucleic acid-based agents
  • Exosomes for delivery of protein therapeutics, including antibodies, antibody fragments, and receptors
  • Targeting of exosomes to tissues and organs of interest
  • Exosomes for small molecule delivery